Compare MGEE & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MGEE | WGS |
|---|---|---|
| Founded | 1855 | 2017 |
| Country | United States | United States |
| Employees | N/A | 1300 |
| Industry | Electric Utilities: Central | Retail: Computer Software & Peripheral Equipment |
| Sector | Energy | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | 2001 | N/A |
| Metric | MGEE | WGS |
|---|---|---|
| Price | $77.23 | $91.78 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $78.00 | ★ $140.71 |
| AVG Volume (30 Days) | 90.1K | ★ 738.9K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | ★ 11.71 | N/A |
| EPS | ★ 3.72 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.02 | $29.98 |
| Revenue Next Year | $2.77 | $24.85 |
| P/E Ratio | ★ $21.44 | $1,251.58 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $76.47 | $55.17 |
| 52 Week High | $94.78 | $170.87 |
| Indicator | MGEE | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 35.79 | 51.26 |
| Support Level | N/A | $78.80 |
| Resistance Level | $82.75 | $95.94 |
| Average True Range (ATR) | 1.68 | 5.68 |
| MACD | -0.50 | 2.40 |
| Stochastic Oscillator | 10.14 | 83.97 |
MGE Energy provides electric service to 170,000 customers and natural gas service to 180,000 customers in Madison, Wisconsin, and surrounding areas. Nearly 90% of customers are residential. The company also owns a 3.6% stake in American Transmission Co. MGE owns interests in two coal power plants that earn guaranteed fixed rates of return, contributing about 20% of earnings.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.